Exclusion of disutilities associated with treatment administration led to lower incremental quality-of-life improvements with oral semaglutide, with discounted quality-adjusted life expectancy benefits of 0.03 QALYs projected versus liraglutide 1.8 mg (Table 3)
This includes patients with androgenetic alopecia, traction alopecia, and telogen effluvium as well
In contrast, a small study found no difference in hepatic FATP5 gene expression between individuals with ( n = 16) and without ( n = 8) hepatic steatosis [19]
doi: 10.1136/emj.2004.020693 [PubMed] 24286945 Alsahli M, Gerich JE
Food and Drug Administration (FDA) found no clear link between GLP-1 RA use and suicidal ideation or behavior, although it emphasized continued pharmacovigilance given the small number of observed events [46]
Generation of pathogenic th17 cells in the absence of TGF- Signaling